Company intelligence / Profile preview

Gem Pharmaceuticals

Birmingham, Alabama, USAexplorium.ai ↗

Ownership: Private
Employees: ~11
Development stage: Phase 2

Overview

Gem Pharmaceuticals developed next-generation anthracycline derivatives designed to retain anti-cancer efficacy while eliminating the cardiotoxicity associated with traditional agents like doxorubicin. Lead compound camsirubicin was advanced for soft tissue sarcoma. Other programs included GPX‑160 and GPX‑200 targeting various cancers. The company is not currently active in clinical development as of mid‑2020s.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

GPX-150

Phase 2

Indications: Cancer, Cardiotoxicity

Beyond the preview

Go deeper on Gem Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gem Pharmaceuticals.

Explore the full profile